BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165:1244-1250. [PMID: 21824126 DOI: 10.1111/j.1365-2133.2011.10565.x] [Cited by in Crossref: 184] [Cited by in F6Publishing: 110] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Defilippis E, Feldman S, Huang W. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015;172:1487-97. [DOI: 10.1111/bjd.13493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
2 Romańska-Gocka K, Cieścińska C, Zegarska B, Schwartz RA, Cieściński J, Olszewska-Słonina D, Czajkowski R. Pyoderma gangrenosum with monoclonal IgA gammopathy and pulmonary tuberculosis. Illustrative case and review. Postepy Dermatol Alergol 2015;32:137-41. [PMID: 26015785 DOI: 10.5114/pdia.2014.40974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ogata K, Takamori H, Ikuta Y, Tanaka H, Ozaki N, Hayashi H, Ogawa K, Doi K. Pyoderma gangrenosum in an abdominal surgical site: a case report. Surg Case Rep 2015;1:122. [PMID: 26943446 DOI: 10.1186/s40792-015-0124-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Galimberti RL, Vacas AS, Bollea Garlatti ML, Torre AC. The role of interleukin-1β in pyoderma gangrenosum. JAAD Case Rep 2016;2:366-8. [PMID: 27709123 DOI: 10.1016/j.jdcr.2016.07.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
5 Dantas SG, Quintella LP, Fernandes NC. Exuberant pyoderma gangrenosum in a patient with autoimmune hepatitis. An Bras Dermatol 2017;92:114-7. [PMID: 28225969 DOI: 10.1590/abd1806-4841.20174871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Mason JM, Thomas KS, Ormerod AD, Craig FE, Mitchell E, Norrie J, Williams HC; U.K. Dermatology Clinical Trials Network's STOP GAP team. Ciclosporin compared with prednisolone therapy for patients with pyoderma gangrenosum: cost-effectiveness analysis of the STOP GAP trial. Br J Dermatol 2017;177:1527-36. [PMID: 28391619 DOI: 10.1111/bjd.15561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Fukaya E, Margolis DJ. Approach to diagnosing lower extremity ulcers: Diagnosing lower extremity ulcers. Dermatol Ther 2013;26:181-6. [DOI: 10.1111/dth.12054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu XR, Mukewar S, Kiran RP, Remzi FH, Hammel J, Shen B. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 2013;7:e171-7. [PMID: 22959399 DOI: 10.1016/j.crohns.2012.08.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
9 Soto Vilches F, Vera-kellet C. Pioderma gangrenoso: terapias clásicas y emergentes. Medicina Clínica 2017;149:256-60. [DOI: 10.1016/j.medcli.2017.04.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
10 Dolci A, Indirli R, Genovese G, Derlino F, Arosio M, Marzano AV. Post-surgical Thyroid Bed Pyoderma Gangrenosum Mimicking Recurrent Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) 2019;10:253. [PMID: 31057489 DOI: 10.3389/fendo.2019.00253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nahi H, Afram G, Brauner H, Talme T, Kuzmina N. Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment. Int J Dermatol 2021;60:e271-3. [PMID: 33751551 DOI: 10.1111/ijd.15504] [Reference Citation Analysis]
12 Lee W-, Choi Y-, Yoo W-. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol 2017;31:e75-7. [DOI: 10.1111/jdv.13736] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pichler M, Larcher L, Holzer M, Exler G, Thuile T, Gatscher B, Tappeiner L, Deluca J, Carriere C, Nguyen VA, Moosbrugger-Martinz V, Schmuth M, Klein GF, Eisendle K. Surgical treatment of pyoderma gangrenosum with negative pressure wound therapy and split thickness skin grafting under adequate immunosuppression is a valuable treatment option: Case series of 15 patients. J Am Acad Dermatol 2016;74:760-5. [PMID: 26979359 DOI: 10.1016/j.jaad.2015.09.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 5.6] [Reference Citation Analysis]
14 Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen M, Guenova E, Dissemond J, Shinkai K, Langan SM. Pyoderma gangrenosum. Nat Rev Dis Primers 2020;6. [DOI: 10.1038/s41572-020-0213-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
15 Weizman AV, Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, Ippoliti A, Panikkath D, Vasiliauskas E, Shih D. Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study. J Cutan Med Surg. 2015;19:125-131. [PMID: 25775631 DOI: 10.2310/7750.2014.14053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tolkachjov SN, Fahy AS, Cerci FB, Wetter DA, Cha SS, Camilleri MJ. Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases. Mayo Clin Proc 2016;91:1267-79. [PMID: 27489052 DOI: 10.1016/j.mayocp.2016.05.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
17 Pourmorteza M, Tawadros F, Bader G, Al-Tarawneh M, Cook E, Shams W, Young M. Successful Treatment of Pyoderma Gangrenosum with Cryoglobulinemia and Hepatitis C. Am J Case Rep 2016;17:434-8. [PMID: 27345376 DOI: 10.12659/ajcr.898611] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Cinats AK, Haber RM. Case Report of Sweet’s Syndrome Associated With Autoimmune Hepatitis. J Cutan Med Surg 2017;21:72-4. [DOI: 10.1177/1203475416665602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Kridin K, Laufer Britva R, Tzur Bitan D, Damiani G, Cohen AD. Is pyoderma gangrenosum associated with solid malignancies? Insights from a population-based cohort study. Australas J Dermatol 2021;62:336-41. [PMID: 34076886 DOI: 10.1111/ajd.13631] [Reference Citation Analysis]
20 Brenner EJ, Long MD. Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease. Curr Opin Gastroenterol 2019;35:330-6. [PMID: 31021924 DOI: 10.1097/MOG.0000000000000538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC; UK Dermatology Clinical Trials Network's STOP GAP Team. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. J Am Acad Dermatol 2016;75:940-9. [PMID: 27502313 DOI: 10.1016/j.jaad.2016.06.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
22 Pichler M, Thuile T, Gatscher B, Tappeiner L, Deluca J, Larcher L, Holzer M, Nguyen V, Exler G, Schmuth M, Klein G, Eisendle K. Systematic review of surgical treatment of pyoderma gangrenosum with negative pressure wound therapy or skin grafting. J Eur Acad Dermatol Venereol 2017;31:e61-7. [DOI: 10.1111/jdv.13727] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
23 Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38:563-572. [PMID: 23914999 DOI: 10.1111/apt.12431] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
24 Penalba-Torres M, Zarco-Olivo C, Calleja-Algarra A. Postsurgical pyoderma gangrenosum: A diagnosis we cannot miss. Med Clin (Barc) 2021:S0025-7753(21)00180-9. [PMID: 34045074 DOI: 10.1016/j.medcli.2021.02.019] [Reference Citation Analysis]
25 Fazel M, Merola JF, Kurtzman DJB. Inflammatory arthritis and crystal arthropathy: Current concepts of skin and systemic manifestations. Clin Dermatol 2018;36:533-50. [PMID: 30047436 DOI: 10.1016/j.clindermatol.2018.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kratzsch D, Ziemer M, Milkova L, Wagner JA, Simon JC, Kendler M. Facial pyoderma gangrenosum in senescence. Case Rep Dermatol 2013;5:295-300. [PMID: 24403893 DOI: 10.1159/000356100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
27 Wang J, Prenner J, Wang W, Sakuraba A, Hyman N, Dalal S, Hurst R, Cohen RD, Umanskiy K, Shogan BD, Alpert L, Rubin DT, Colwell J, Pekow J. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:1365-72. [PMID: 32383278 DOI: 10.1111/apt.15766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Flynn RL, Chowdhury MH, Rudolph J, Einstein S. Rare Presentation of Postsurgical Pyoderma Gangrenosum Presenting as Necrotizing Soft Tissue Infection. Adv Skin Wound Care 2019;32:507-11. [PMID: 31498172 DOI: 10.1097/01.ASW.0000579692.74662.bb] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Demirdover C, Geyik A, Vayvada H. Necrotising fasciitis or pyoderma gangrenosum: A fatal dilemma. Int Wound J 2019;16:1347-53. [PMID: 31418533 DOI: 10.1111/iwj.13196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Ohtsuka M, Yamamoto T. Rare association of pyoderma gangrenosum and palmoplantar pustulosis: a case report and review of the previous works. J Dermatol. 2014;41:732-735. [PMID: 24986043 DOI: 10.1111/1346-8138.12543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Monari P, Moro R, Motolese A, Misciali C, Baraldi C, Fanti PA, Caccavale S, Puviani M, Olezzi D, Zampieri P, Trevisan G, Nan K, Fiorentini C, Pellacani G, Gualdi G. Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. Int Wound J 2018;15:875-9. [PMID: 29877043 DOI: 10.1111/iwj.12939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
32 Schoch JJ, Tolkachjov SN, Cappel JA, Gibson LE, Davis DM. Pediatric Pyoderma Gangrenosum: A Retrospective Review of Clinical Features, Etiologic Associations, and Treatment. Pediatr Dermatol. 2017;34:39-45. [PMID: 27699861 DOI: 10.1111/pde.12990] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
33 Wollina U. Pyoderma gangrenosum—a systemic disease? Clinics in Dermatology 2015;33:527-30. [DOI: 10.1016/j.clindermatol.2015.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
34 Haag C, Hansen T, Hajar T, Latour E, Keller J, Shinkai K, Ortega-Loayza AG. Comparison of Three Diagnostic Frameworks for Pyoderma Gangrenosum. J Invest Dermatol 2021;141:59-63. [PMID: 32445742 DOI: 10.1016/j.jid.2020.04.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
35 Abdelkader HA, Abdel-Galeil Y, Elbendary A, El-Mofty M, Abdel-Halim MRE. Multiple Skin Ulcers in a Rheumatoid Arthritis Patient: Answer. Am J Dermatopathol 2020;42:146-7. [PMID: 31990704 DOI: 10.1097/DAD.0000000000001326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Soleimani T, Sasor SE, Spera L, Eppley BE, Socas J, Chu MW, Tholpady SS. Pediatric pyoderma gangrenosum: is it just big wounds on little adults? Journal of Surgical Research 2016;206:113-7. [DOI: 10.1016/j.jss.2016.06.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
37 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 143] [Article Influence: 61.3] [Reference Citation Analysis]
38 Partridge ACR, Bai JW, Rosen CF, Walsh SR, Gulliver WP, Fleming P. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials. Br J Dermatol 2018;179:290-5. [PMID: 29478243 DOI: 10.1111/bjd.16485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther 2012;25:158-72. [PMID: 22741935 DOI: 10.1111/j.1529-8019.2012.01488.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
40 Carvalho LR, Zanuncio VV, Gontijo B. Pyoderma gangrenosum with renal and splenic impairment--case report. An Bras Dermatol 2013;88:150-3. [PMID: 24346905 DOI: 10.1590/abd1806-4841.20132448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
41 Tannenbaum R, Strunk A, Garg A. Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States. J Am Acad Dermatol 2019;80:1533-7. [PMID: 30738122 DOI: 10.1016/j.jaad.2019.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kolios A, Maul J, Meier B, Kerl K, Traidl‐hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini A, French L. Canakinumab in adults with steroid‐refractory pyoderma gangrenosum. Br J Dermatol 2015;173:1216-23. [DOI: 10.1111/bjd.14037] [Cited by in Crossref: 54] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
43 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA, Williams HC; UK Dermatology Clinical Trials Network’s STOP GAP Team. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 2015;350:h2958. [PMID: 26071094 DOI: 10.1136/bmj.h2958] [Cited by in Crossref: 121] [Cited by in F6Publishing: 69] [Article Influence: 20.2] [Reference Citation Analysis]
45 Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol 2016;175:1070-2. [PMID: 27060666 DOI: 10.1111/bjd.14619] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
46 Yi L, Qun S, Wenjie Z, Wen Z, Jian L, Yan Z, Fengchun Z. The presenting manifestations of subcutaneous panniculitis-like T-cell lymphoma and T-cell lymphoma and cutaneous γδ T-cell lymphoma may mimic those of rheumatic diseases: a report of 11 cases. Clin Rheumatol 2013;32:1169-75. [PMID: 23588884 DOI: 10.1007/s10067-013-2258-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
47 Jockenhöfer F, Herberger K, Schaller J, Hohaus KC, Stoffels-Weindorf M, Ghazal PA, Augustin M, Dissemond J. Tricenter analysis of cofactors and comorbidity in patients with pyoderma gangrenosum. J Dtsch Dermatol Ges 2016;14:1023-30. [PMID: 27767288 DOI: 10.1111/ddg.12791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Maverakis E, Le ST, Callen J, Wollina U, Marzano AV, Wallach D, Schadt C, Martinez-alvarado YC, Cheng MY, Ma C, Merleev A, Ormerod A, Craig F, Jockenhofer F, Dissemond J, Salva K, Williams HC, Fiorentino D. New validated diagnostic criteria for pyoderma gangrenosum. Journal of the American Academy of Dermatology 2019;80:e87-8. [DOI: 10.1016/j.jaad.2018.08.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
49 Kaomongkolgit R, Subbalekha K, Sawangarun W, Thongprasom K. Pyoderma gangrenosum-like oral ulcerations in an elderly patient. Gerodontology 2015;32:309-13. [DOI: 10.1111/ger.12158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Carmagnola D, Pispero A, Canciani E, Dellavia C, Barbieri C, Lodi G, Varoni EM. Dental treatment of a rare case of pyoderma gangrenosum with aggressive periodontal disease. J Am Dent Assoc 2018;149:794-800. [PMID: 29945713 DOI: 10.1016/j.adaj.2018.04.025] [Reference Citation Analysis]
51 Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, el-Azhary RA, Mcevoy MT, Camilleri MJ. Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014. Journal of the American Academy of Dermatology 2015;73:615-22. [DOI: 10.1016/j.jaad.2015.06.054] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
52 Kridin K, Cohen AD, Amber KT. Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2018;19:479-87. [PMID: 29721816 DOI: 10.1007/s40257-018-0356-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 9.7] [Reference Citation Analysis]
53 Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176:1588-1598. [PMID: 27943240 DOI: 10.1111/bjd.15226] [Cited by in Crossref: 101] [Cited by in F6Publishing: 70] [Article Influence: 25.3] [Reference Citation Analysis]
54 González-Moreno J, Ruíz-Ruigomez M, Callejas Rubio JL, Ríos Fernández R, Ortego Centeno N. Pyoderma gangrenosum and systemic lupus erythematosus: a report of five cases and review of the literature. Lupus 2015;24:130-7. [PMID: 25199808 DOI: 10.1177/0961203314550227] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
55 Donmez S, Pamuk ON, Gedik M, A K R, Bulut G. A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab. Int J Rheum Dis 2014;17:471-5. [PMID: 24460826 DOI: 10.1111/1756-185X.12274] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 3.1] [Reference Citation Analysis]
56 Plumptre I, Knabel D, Tomecki K. Pyoderma Gangrenosum: A Review for the Gastroenterologist. Inflamm Bowel Dis 2018;24:2510-7. [PMID: 29788368 DOI: 10.1093/ibd/izy174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
57 Clarke K, Chintanaboina J. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. Clin Rev Allergy Immunol 2019;57:179-93. [PMID: 29754190 DOI: 10.1007/s12016-018-8690-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
58 Cabalag MS, Wasiak J, Lim SW, Raiola FB. Inpatient Management of Pyoderma Gangrenosum: Treatments, Outcomes, and Clinical Implications. Annals of Plastic Surgery 2015;74:354-60. [DOI: 10.1097/sap.0b013e31829565f3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 4.2] [Reference Citation Analysis]
59 Alonso-León T, Hernández-Ramírez HH, Fonte-Avalos V, Toussaint-Caire S, E Vega-Memije M, Lozano-Platonoff A. The great imitator with no diagnostic test: pyoderma gangrenosum. Int Wound J 2020;17:1774-82. [PMID: 32779354 DOI: 10.1111/iwj.13466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, Roth H, Rabe E, Karrer S, Renner R. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136. [PMID: 24010984 DOI: 10.1186/1750-1172-8-136] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 9.5] [Reference Citation Analysis]
61 Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2017;18:355-372. [PMID: 28224502 DOI: 10.1007/s40257-017-0251-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 52] [Article Influence: 32.7] [Reference Citation Analysis]
62 Nusbaum KB, Ortega-Loayza AG, Kaffenberger BH. Health-related domains of quality of life in pyoderma gangrenosum: A qualitative analysis. J Am Acad Dermatol 2021:S0190-9622(21)01033-1. [PMID: 34058281 DOI: 10.1016/j.jaad.2021.05.040] [Reference Citation Analysis]
63 Haag CK, Nutan F, Cyrus JW, Satpathy J, Shinkai K, Ortega Loayza AG. Pyoderma gangrenosum misdiagnosis resulting in amputation: A review. J Trauma Acute Care Surg 2019;86:307-13. [DOI: 10.1097/ta.0000000000002096] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
64 Bingoel AS, Krezdorn N, Kaltenborn A, Dastagir K, Jokuszies A, Mett TR, Vogt PM. The surgical approach to Pyoderma gangrenosum: A retrospective monocenter study. Wound Repair Regen 2021;29:478-85. [PMID: 33835625 DOI: 10.1111/wrr.12918] [Reference Citation Analysis]
65 Sawka E, Zhou A, Latour E, Friedman M, Ortega-Loayza AG. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. Clin Rheumatol 2021. [PMID: 34002351 DOI: 10.1007/s10067-021-05768-7] [Reference Citation Analysis]
66 Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 2018;14:225-33. [PMID: 29406827 DOI: 10.1080/1744666X.2018.1438269] [Cited by in Crossref: 41] [Cited by in F6Publishing: 9] [Article Influence: 13.7] [Reference Citation Analysis]
67 Tay DZ, Tan KW, Tay YK. Pyoderma gangrenosum: a commonly overlooked ulcerative condition. J Family Med Prim Care 2014;3:374-8. [PMID: 25657946 DOI: 10.4103/2249-4863.148113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
68 Fletcher J, Alhusayen R, Alavi A. Recent advances in managing and understanding pyoderma gangrenosum. F1000Res 2019;8:F1000 Faculty Rev-2092. [PMID: 31885859 DOI: 10.12688/f1000research.19909.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
69 Jockenhöfer F, Klode J, Kröger K, Roesch A, Al Ghazal P, Dissemond J. Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012. Int Wound J 2016;13:951-6. [PMID: 26250591 DOI: 10.1111/iwj.12463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
70 Montagnon CM, Fracica EA, Patel AA, Camilleri MJ, Murad MH, Dingli D, Wetter DA, Tolkachjov SN. Pyoderma gangrenosum in hematologic malignancies: A systematic review. J Am Acad Dermatol 2020;82:1346-59. [PMID: 31560977 DOI: 10.1016/j.jaad.2019.09.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
71 Almukhtar R, Armenta AM, Martin J, Goodwin BP, Vincent B, Lee B, Dacso MM. Delayed diagnosis of post-surgical pyoderma gangrenosum: A multicenter case series and review of literature. Int J Surg Case Rep 2018;44:152-6. [PMID: 29501933 DOI: 10.1016/j.ijscr.2018.02.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
72 Adışen E, Erduran F, Gürer MA. Pyoderma Gangrenosum: A Report of 27 Patients. Int J Low Extrem Wounds 2016;15:148-54. [PMID: 27009790 DOI: 10.1177/1534734616639172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
73 Pukar C, Sudha A, Punam P. Simultaneous occurrence of Pyoderma Gangrenosum and Palmoplantar Pustular Psoriasis: Is it an association or coincidental findings? Clin Case Rep 2021;9:410-5. [PMID: 33489191 DOI: 10.1002/ccr3.3544] [Reference Citation Analysis]
74 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
75 Thomas KS, Batchelor JM, Bath-hextall F, Chalmers JR, Clarke T, Crowe S, Delamere FM, Eleftheriadou V, Evans N, Firkins L, Greenlaw N, Lansbury L, Lawton S, Layfield C, Leonardi-bee J, Mason J, Mitchell E, Nankervis H, Norrie J, Nunn A, Ormerod AD, Patel R, Perkins W, Ravenscroft JC, Schmitt J, Simpson E, Whitton ME, Williams HC. A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. Programme Grants Appl Res 2016;4:1-488. [DOI: 10.3310/pgfar04180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Deregnaucourt D, Buche S, Coopman S, Basraoui D, Turck D, Delaporte E. Pyoderma gangrenosum avec localisations pulmonaires traité par infliximab. Annales de Dermatologie et de Vénéréologie 2013;140:363-6. [DOI: 10.1016/j.annder.2013.01.428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
77 Kim D, Hur SM, Lee JS, Chin S, Lim CW, Kim Z. Pyoderma Gangrenosum Mimicking Wound Infection after Breast Cancer Surgery. J Breast Cancer 2021;24:409-16. [PMID: 34128363 DOI: 10.4048/jbc.2021.24.e25] [Reference Citation Analysis]
78 Ighani A, Al‐mutairi D, Rahmani A, Weizman A, Piguet V, Alavi A. Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. Br J Dermatol 2019;180:672-3. [DOI: 10.1111/bjd.17347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol 2018;178:595-602. [PMID: 26202386 DOI: 10.1111/bjd.13955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
80 Mikail M, Wilson A. Infliximab treatment for large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: A case report. SAGE Open Med Case Rep 2020;8:2050313X20964113. [PMID: 33149915 DOI: 10.1177/2050313X20964113] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologika und Immunglobuline für die Therapie des Pyoderma gangraenosum - Analyse von 52 Patienten. J Dtsch Dermatol Ges 2019;17:32-42. [PMID: 30615279 DOI: 10.1111/ddg.13741_g] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Beber AA, Knob CF, Shons KR, Neumaier W, da Silva JC, Monticielo OA. [Pyoderma gangrenosum associated with rheumatoid arthritis: a case report]. Rev Bras Reumatol 2014;54:322-5. [PMID: 25627229 DOI: 10.1016/j.rbr.2013.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
83 Herberger K. [Pyoderma gangrenosum]. Hautarzt 2016;67:753-63. [PMID: 27492434 DOI: 10.1007/s00105-016-3847-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
84 Shavit E, Cecchini M, Limacher JJ, Walsh S, Wentworth A, Davis MDP, Alavi A. Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature [Formula: see text]. J Cutan Med Surg 2021;25:371-6. [PMID: 33541119 DOI: 10.1177/1203475420988864] [Reference Citation Analysis]
85 Sakiyama M, Kobayashi T, Nagata Y, Fujimoto N, Satoh T, Tajima S. Bullous pyoderma gangrenosum: a case report and review of the published work. J Dermatol 2012;39:1010-5. [PMID: 22974277 DOI: 10.1111/j.1346-8138.2012.01676.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
86 McPhie ML, Fletcher J, Machado MO, Carvalho AF, Piguet V, Alavi A. A Systematic Review of Depression and Anxiety in Adults with Pyoderma Gangrenosum. Adv Skin Wound Care 2021;34:432-6. [PMID: 34260421 DOI: 10.1097/01.ASW.0000755920.76330.21] [Reference Citation Analysis]
87 Vacas AS, Torre AC, Bollea-garlatti ML, Warley F, Galimberti RL. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol 2017;56:386-91. [DOI: 10.1111/ijd.13591] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
88 Kaffenberger BH, Hinton A, Krishna SG. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 2018;79:659-663.e2. [PMID: 29438762 DOI: 10.1016/j.jaad.2018.02.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
89 Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges 2019;17:32-41. [PMID: 30592563 DOI: 10.1111/ddg.13741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
90 Inoue S, Furuta JI, Fujisawa Y, Onizawa S, Ito S, Sakiyama M, Kobayashi K, Kanou T, Iijima S, Ohi T, Okubo C, Moriyama Y, Okiyama N, Fujimoto M. Pyoderma gangrenosum and underlying diseases in Japanese patients: A regional long-term study. J Dermatol 2017;44:1281-4. [PMID: 28635156 DOI: 10.1111/1346-8138.13937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
91 Stiegler JD, Lucas CT, Sami N. Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone. JAAD Case Rep 2017;3:387-9. [PMID: 28879220 DOI: 10.1016/j.jdcr.2017.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
92 Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017;10:1119-28. [PMID: 28715916 DOI: 10.1080/17512433.2017.1356719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
93 Hobbs MM, Byler R, Latour E, Bonomo L, Hennessy K, Cruz-Diaz CN, Shinohara MM, Seminario-Vidal L, Shinkai K, Ortega-Loayza AG. Treatment of pyoderma gangrenosum: A multicenter survey-based study assessing satisfaction and quality of life. Dermatol Ther 2021;34:e14736. [PMID: 33394563 DOI: 10.1111/dth.14736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
94 Terziroli Beretta-piccoli B, Invernizzi P, Gershwin ME, Mainetti C. Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinic Rev Allerg Immunol 2017;53:394-412. [DOI: 10.1007/s12016-017-8649-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
95 Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol 2018;79:1009-22. [PMID: 29653213 DOI: 10.1016/j.jaad.2017.11.063] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 10.3] [Reference Citation Analysis]
96 Marzano AV, Borghi A, Wallach D, Cugno M. A Comprehensive Review of Neutrophilic Diseases. Clinic Rev Allerg Immunol 2018;54:114-30. [DOI: 10.1007/s12016-017-8621-8] [Cited by in Crossref: 63] [Cited by in F6Publishing: 36] [Article Influence: 15.8] [Reference Citation Analysis]
97 Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, James WD, Micheletti RG, Rosenbach M, Mostaghimi A. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatol. 2018;154:409-413. [PMID: 29450453 DOI: 10.1001/jamadermatol.2017.5978] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
98 Eisendle K, Thuile T, Deluca J, Pichler M. Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases. Adv Wound Care (New Rochelle) 2020;9:405-25. [PMID: 32320362 DOI: 10.1089/wound.2020.1160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
99 Shah M, Sachdeva M, Gefri A, Jfri A. Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review. Int J Dermatol 2019;59:154-8. [DOI: 10.1111/ijd.14637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
100 Steele RB, Nugent WH, Braswell SF, Frisch S, Ferrell J, Ortega-Loayza AG. Pyoderma gangrenosum and pregnancy: an example of abnormal inflammation and challenging treatment. Br J Dermatol 2016;174:77-87. [PMID: 26474193 DOI: 10.1111/bjd.14230] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
101 Xia FD, Liu K, Lockwood S, Butler D, Tsiaras WG, Joyce C, Mostaghimi A. Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum-A retrospective analysis. J Am Acad Dermatol 2018;78:310-314.e1. [PMID: 28947285 DOI: 10.1016/j.jaad.2017.09.040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
102 Gupta AS, Ortega-Loayza AG. Ocular pyoderma gangrenosum: A systematic review. J Am Acad Dermatol 2017;76:512-8. [PMID: 27836332 DOI: 10.1016/j.jaad.2016.08.049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
103 Kwiatt M, Kawata M. Avoidance and management of stomal complications. Clin Colon Rectal Surg 2013;26:112-21. [PMID: 24436659 DOI: 10.1055/s-0033-1348050] [Cited by in Crossref: 76] [Cited by in F6Publishing: 33] [Article Influence: 10.9] [Reference Citation Analysis]
104 George C, Deroide F, Rustin M. Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med (Lond). 2019;19:224-228. [PMID: 31092515 DOI: 10.7861/clinmedicine.19-3-224] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 29.0] [Reference Citation Analysis]
105 Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel topical therapy for resistant and early peristomal pyoderma gangrenosum. Int Wound J 2019;16:1136-43. [PMID: 31298491 DOI: 10.1111/iwj.13164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
106 Gerard AJ, Feldman SR, Strowd L. Quality of Life of Patients With Pyoderma Gangrenosum and Hidradenitis Suppurativa. J Cutan Med Surg 2015;19:391-6. [DOI: 10.1177/1203475415575013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
107 Landis ET, Taheri A, Jorizzo JL. Gulliver's sign: A recognizable transition from inflammatory to healing stages of pyoderma gangrenosum. J Dermatolog Treat 2015;26:171-2. [PMID: 24552122 DOI: 10.3109/09546634.2014.883061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
108 Wat H, Haber RM. Trends in the Association between Pyoderma Gangrenosum and Autoimmune Hepatitis: Case Report and Review of the Literature. J Cutan Med Surg 2014;18:345-52. [DOI: 10.2310/7750.2013.13177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
109 Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol 2018;178:363-8. [PMID: 28742926 DOI: 10.1111/bjd.15850] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
110 Barbosa NS, Tolkachjov SN, el-Azhary RA, Davis MD, Camilleri MJ, Mcevoy MT, Bridges AG, Wetter DA. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. Journal of the American Academy of Dermatology 2016;75:931-9. [DOI: 10.1016/j.jaad.2016.05.044] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]